EGFR Gene, Targeted Mutation Analysis, 51 Mutation Panel, Tumor
Use
This test is useful for identifying non-small cell lung cancers that may respond to epidermal growth factor receptor-targeted therapies. By analyzing the mutation status of the EGFR gene, it aids in selecting patients who might benefit from EGFR-targeted treatment. Molecular genetic profiling, as performed in this test, is crucial for identifying actionable mutations and minimizing treatment costs and associated risks.
Special Instructions
Not provided.
Limitations
A negative (wildtype) result does not rule out the presence of mutations that may be present but below the detection limits of this assay (approximately 10%). It also does not exclude the presence of other activating mutations in the EGFR gene. Not all patients with detected activating EGFR mutations will respond to EGFR-targeted therapies. Rare genetic alterations, such as polymorphisms, could result in false-negative or false-positive results.
New York Approved
Methodology
PCR-based
Biomarkers
EGFR
Gene
LOINC Codes
- 21665-5 - EGFR gene Mut Anl Bld/T
- 50397-9 - Mol dx interp Bld/T Ql
- 21665-5 - EGFR gene Mut Anl Bld/T
- 69047-9 - Geneticist review
- 31208-2 - Specimen source
- 80398-1 - Unique ID Current sample
- 18771-6 - Provider signing name
Result Turnaround Time
4-7 days
Related Documents
For more information, please review the documents below
Specimen
Tissue (FFPE)
Volume
Submit 3, if available, or 2 of the following specimens.
Minimum Volume
>1000 cells
Container
Formalin-fixed, paraffin-embedded (FFPE) tissue block or Slides
Collection Instructions
Submit a formalin-fixed, paraffin-embedded (FFPE) tissue block with acceptable amount of tumor tissue.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | Ambient (preferred) |